San Diego-dependent Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug industry in February just after revealing promising information from a mid-stage trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when given to be a weekly injection and in March the co